Table 1.

Demographics, Clinical Characteristics, and Postvaccine Scan Details of Patients With and Without Vaccine-Related Lymphadenopathy

Demographics, Clinical Characteristics, and Scan Details		With Adenopathy (n = 21)	Without Adenopathy (n = 211)	All Patients (N = 232)	p Value
Age (y)	Median [range]	69 [52–82]	71 [40–96]	71 [40–96]	0.49
Sex	Male	3	85	88	0.019
	Female	18	126	144
Race	White	19	185	204	0.54
	Asian	2	11	13
	Black	0	7	7
	Other	0	8	8
Smoking	Never	6	67	73	0.21
	Former	14	106	120
	Current	1	38	39
Tumor types	NSCLC	18	182	200	0.90
	SCLC	1	11	12
	Mesothelioma	1	9	10
	Other	1	9	10
Tumor stage at vaccination	Advanced	14	162	176	0.29
	Not advanced	7	49	56
Vaccine types	BNT162b2	15	189	204	0.026
	mRNA-1273	6	22	28
Postvaccine scan type	CT only	18	192	210	0.092
	PET/CT onlya	0	10	10
	CT and PET/CTa	3	9	12
Postvaccine scan time point	1 time point	20	161	181	0.052
	2–4 time points	1	50	51
Postvaccine scan timing	Between two dosesb only	2	44	46	0.13
	After second dose only	18	135	153
	Between two doses and after second dose	1	32	33
Median time between vaccine dose and scan (wk)	Pre-CT to first dose	5.4	5.4	5.4	0.58
	First dose to post-CTc	4.8	5.0	5.0	0.95
	Second dose to post-CTc	1.7	1.7	1.7	0.80

CT, computed tomography; PET, positron emission tomography.

^aThe rate of lymphadenopathy did not differ significantly between patients with and without postvaccine PET/CT (3 of 22 versus 18 of 210, respectively; p = 0.43).

^b“Between two doses” indicates the scans performed after the first vaccine dose before the second dose.

^cTime was calculated from each vaccine dose to the postvaccine scan, using the first postvaccine scan in patients with more than one postvaccine scans.